Skip to content

Main Navigation

  • About us
    • History
    • Mission, vision & values
    • Leadership
    • Scientific advisors
    • Our team
    • Social impact (CSR)
  • Science & Services
    • Contexts of use
      • Trial design and analyses
      • Program strategies and efficiencies
      • Special/specific populations
      • Special considerations
      • Regulatory interactions
    • Pharmetheus Platforms
      • Model-Informed Drug Development
      • PBPK & PBBM
      • Pharmacometrics
      • QSP
    • Solutions
      • Milestone Analysis
      • Embedded Scientist
      • Expert Advice
      • Scientific Publication
    • Specific services
      • Model-Informed Bioequivalence & Biosimilarity
      • Accelerated submission
      • Concentration-QTc (C-QTc) modeling
      • Data-driven strategies for pediatric success
    • Publications
    • Case studies
    • Training workshops
  • Careers
    • Working with us
    • Open positions
    • Employee stories
  • Events
  • News
  • Contact us
  • LinkedIn

Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response Modelling

PAGE 29 (2021) Abstr 9857.
Ibrahim MMA, Plan EL, Jönsson S, Chen C, Karlsson MO.
CNSConferenceMIDDPharmacometricsTrial design and analysis

Pharmetheus Affiliates

Portrait-of-Elodie-Plan_Pharmetheus-1
Chief Business Development Officer & Deputy CEO

Elodie Plan

See bio
Portrait-of-Siv-Jonsson-Pharmetheus
Senior Director, R&D Scientist

Siv Jönsson

See bio
Portrait-of-Mats-Karlsson_Pharmetheus
Scientific Advisor & Board Member

Mats Karlsson

See bio

Contact

Pharmetheus AB
Kungsängstull 4
753 19 Uppsala, Sweden

Visiting address: Dragarbrunnsgatan 77, 5th floor

Contact us

Links

  • Home
  • Newsletter
  • LinkedIn
  • Whistleblower
  • Privacy Policy
  • Cookie Policy
  • Consent Preferences

Services

  • Contexts of use
  • Pharmetheus platforms
  • Solutions
  • Case studies
  • Publications

About

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.